Tenax Therapeutics (NASDAQ:TENX) shares traded 1.24% up during most recent session to reach at the closing price of $1.63. The stock exchanged hands 511835 shares versus average trading capacity of 1.08 Million shares, yielding a market cap of $1.97 Million. Wall Street analysts covering the stock are projecting that the stock will reach $9.25 within the next 52-weeks. The mean target projections are based on 1 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Tenax Therapeutics (NASDAQ:TENX) high price target of $9.25 and with a conservative view have low price target of $9.25.
Ladenburg Thalmann “Upgrades” Tenax Therapeutics (NASDAQ:TENX) in a research note issued to investors on 5/18/17 to Buy.
On the other hand the company has Relative Strength Index (RSI 14) of 58.69 along with Average True Range (ATR 14) of 0.27, Consequently Tenax Therapeutics (NASDAQ:TENX)’s weekly and monthly volatility is 29.74%, 17.34% respectively. The company’s beta value is at 1.11.
In terms of Buy, Sell or Hold recommendations, Tenax Therapeutics (NASDAQ:TENX) has analysts’ mean recommendation of 0. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Tenax Therapeutics (NASDAQ:TENX)’s minimum EPS for the current quarter is at $-0.31 and can go high up to $-0.31. The consensus mean EPS for the current quarter is at $-0.31 derived from a total of 1 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.87 earnings per share for the same quarter during last year.
Previously Tenax Therapeutics (NASDAQ:TENX) reported $-1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $-1.46 by $0.41. The company posted an earnings surprise of 28.1%.
Currently Tenax Therapeutics (NASDAQ:TENX)’s shares owned by insiders are 16.99%, whereas shares owned by institutional owners are 58.7%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0%.
Tenax Therapeutics (NASDAQ:TENX)’s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0. Its book value per share for the most recent quarter is $3.38 while its price to book ratio for the same period is 0.48, as for as the company’s cash per share for the most recent quarter is $3.97, however its price to cash per share ratio for the same period is 0.41. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.